Daniel Gordon Kirby - 10 Feb 2026 Form 4 Insider Report for IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Role
Chief Commercial Officer
Signature
/s/ Daniel Gordon Kirby
Issuer symbol
IOVA
Transactions as of
10 Feb 2026
Net transactions value
-$42,770
Form type
4
Filing time
12 Feb 2026, 17:00:14 UTC
Previous filing
06 Jun 2025
Next filing
26 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kirby Daniel Gordon Chief Commercial Officer C/O IOVANCE BIOTHERAPEUTICS, INC., 825 INDUSTRIAL ROAD, SUITE 100, SAN CARLOS /s/ Daniel Gordon Kirby 12 Feb 2026 0002055001

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IOVA Common Stock Options Exercise $0 +39,996 +133% $0.000000 69,996 10 Feb 2026 Direct F1
transaction IOVA Common Stock Tax liability $42,770 -16,450 -24% $2.60 53,546 10 Feb 2026 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IOVA Restricted Stock Units Options Exercise $0 -39,996 -33% $0.000000 80,004 10 Feb 2026 Common Stock 39,996 Direct F4, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
F2 Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
F3 Represents the common stock remaining after deducting the common stock withheld for taxes.
F4 Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F5 The remaining RSUs will vest in equal quarterly installments.
F6 Such aggregate number reflects the remainder of such RSUs granted on February 10, 2025, but does not include any other RSUs held by such Reporting Person.